Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-06-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: donorcelltransplantationmarrowbone
  Phrases that lowered it: healthydiseasessinglepatientscoronary
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Collaborators: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 26 (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 75.6% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Drugs with FDA adverse-event history: 7 (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 64628 (raises risk) · Drug's FDA history
• Maximum age: 49 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 17949 (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 · started 2008 · scored riskier than 61% of active trials completed
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant NCT00796068 · started 2009 · scored riskier than 45% of active trials completed
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01529827 · started 2012 · scored riskier than 91% of active trials completed
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children NCT01858740 · started 2014 · scored riskier than 77% of active trials completed
• Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies NCT01682226 · started 2012 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.